CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

Company Statements 2021

Biocon Biologics  /  News – Posts  /  Company Statements  /  Company Statements 2021

Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
  • Sat, 25-Sep-2021
  • Posted by: Biocon Biologics
No Comments

Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
  • Wed, 28-Apr-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
  • Mon, 26-Apr-2021
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
  • Fri, 12-Feb-2021
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Safe Harbour | Privacy Policy | Terms of Use © 2022, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share